The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment

Clinical Endocrinology

Volumn 50, Issue 4, 1999, Pages 517-527

  Pasquali, Renato ^a   Gambineri, Alessandra ^b   Anconetani, Bruno ^b   Vicennati, Valentina ^b   Colitta, Donatella ^b   Caramelli, Elisabetta ^b   Casimirri, Francesco ^b   Morselli Labate, Antonio Maria ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CHOLESTEROL; CYPROTERONE ACETATE; DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL; FOLLITROPIN; GESTAGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LUTEINIZING HORMONE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL;

ACANTHOSIS NIGRICANS; ACNE; ADULT; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY FAT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIRSUTISM; HORMONAL THERAPY; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN RESISTANCE; LONG TERM CARE; METABOLIC DISORDER; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; BLOOD GLUCOSE; BODY COMPOSITION; BODY MASS INDEX; C-PEPTIDE; CHOLESTEROL, HDL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN; POLYCYSTIC OVARY SYNDROME; PROGESTINS; TESTOSTERONE;

EID: 0032931526     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.1999.00701.x     Document Type: Article

References (48)

1. Apter, D., Butzow, T., Laughlin, G.A. & Yen, S.S.C. (1995) Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. Journal of Clinical Endocrinology and Metabolism, 80, 2966-2973.
2. Bjorntorp, P. (1996) The regulation of adipose tissue distribution in humans. International Journal of Obesity, 20, 291-302.
3. Bringer, J., Lefebvre, P., Boulet, F., Grigorescu, F., Renard, E., Hedou, B., Orsetti, A. & Jaffiol, C. (1993) Body composition and regional fat distribution in polycystic ovary syndrome. Relationship to hormonal and metabolic parameters. Annals New York Academy of Science, 687, 115-123.
4. Colditz, G.A., Willet, W.C., Stampfer, M.J., Rosner, B., Speizer, F.E. & Hennekens, C.H. (1987) Menopause and the risk of coronary heart disease in women. New England Journal of Medicine, 316, 1105-1110.
5. Conway, G.S., Agrawal, R., Betteridge, D.J. & Jacobs, H.S. (1992) Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clinical Endocrinology (Oxford), 37, 119-125.
6. Dahlgren, E., Johansson, S., Lindstedt, G., Knutsson, F., Odén, A., Janson, P.O., Mattson, L.A., Crona, N. & Lundberg, P.A. (1992a) Women with polycystic ovary syndrome wedge resected in 1956-65: a long-term follow-up focusing on natural history and circulating hormones. Fertility and Sterility, 57, 505-513.
7. Dahlgren, E., Johansson, S., Lapidus, L., Odén, A. & Janson, P.O. (1992b) Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstetrics and Gynecology Scandinavica, 71, 599-604.
8. Dunaif, A., Mandeli, J., Fluhr, H. & Dobrjansky, A. (1988) The impact of obesity and chronic hyperinsulinaemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 66, 131-139.
9. Dunaif, A. & Finegood, D.T. (1996) β-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 81, 942-947.
10. Dunaif, A., Scott, D., Finegood, D., Quintana, B. & Whitcomb, R. (1996) The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 81, 3299-3306.
11. Dunaif, A. (1997) Insulin resistance and the polycystic ovary syndrome: mechanisms and implication for pathogenesis. Endocrine Review, 18, 774-800.
12. Ehrmann, D.A., Cavaghan, M.K., Imperial, J., Sturis, J., Rosenfield, R.L. & Polonsky, K.S. (1997) Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 82, 524-530.
13. Ferriman, D. & Gallwey, J.D. (1961) Clinical assessment of body hair growth in women. Journal of Clinical Endocrinology and Metabolism, 21, 1440-1445.
14. Franks, S. (1995) Polycystic ovary syndrome. New England Journal of Medicine, 333, 853-861.
15. Freinkel, R.K., Freinkel, N. (1987) Cutaneous manifestation of endocrine disorders. In: Dermatology in General Medicine, 3rd edn (eds T.B. Fitzpatrik, A.Z. Elsen & K Wolff), pp. 2063-2081. McGraw-Hill, New York, NY.
16. Godsland, I.F., Crook, D. & Simpson, R. (1990) The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. New England Journal of Medicine, 323, 1375-1381.
17. Godsland, I.F., Walton, C., Felton, C., Prouder, A., Patel, A. & Winn, V. (1991) Insulin resistance, secretion, and metabolism in users of oral contraceptives. Journal of Clinical Endocrinology and Metabolism, 74, 64-70.
18. Goldzieher, J.W. & Young, R.L. (1992) Selected aspects of polycystic ovarian disease. Endocrinology and Metabolism Clinics of North America, 21, 141-171.
19. Gossain, V.V., Sherma, N.K., Michelakis, A.M. & Ruvner, D.R. (1983) Effect of oral contraceptives on plasma glucose, insulin, and glucagon levels. American Journal of Obstetrics and Gynecology, 147, 618-623.
20. Haarbo, J., Marslew, U., Gotfredsen, A. & Christiansen, C. (1991) Postmenopausal hormone replacment therapy prevents central distribution of body fat after menopause. Metabolism, 40, 1323-1326.
21. Holte, J. (1996) Disturbances in insulin secretion and sensitivity in women with polycystic ovary syndrome. Baillière's Clinics in Endocrinology and Metabolism, 10, 221-247.
22. Jakubowicz, D.J. & Nestler, J.E. (1997) 17alpha-hydroxyprogesterone responses to leuprolide and scrum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss. Journal of Clinical Endocrinology and Metabolism, 82, 556-560.
23. Kiddy, D.S., Hamilton-Fairley, D., Bush, A., Short, F., Anyaouku, V., Reed, M.J. & Franks, S. (1992) Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clinical Endocrinology (Oxford), 36, 105-111.
24. Koritowski, M.T., Mokan, M., Horwitz, M.J. & Berga, S.L. (1995) Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 80, 3327-3334.
25. Kritz-Silverstein, D. & Barrett-Connor, E. (1996) Long-term postmenopausal hormone use, obesity, and fat distribution in older women. Journal of American Medical Association, 275, 46-49.
26. Matthews, K.A., Meilahan, E., Kuller, L.H., Kelsey, S.F., Caggiula, A.W. & Wing, R.R. (1989). Menopause and risk factors for coronary heart disease. New England Journal of Medicine, 321, 641-646.
27. McKeigue, P. (1996) Cardiovascular disease and diabetes in women with polycystic ovary syndrome. Baillière's Clinics in Endocrinology and Metabolism, 10, 311-318.
28. Nestler, J.E., Barlascini, C.O., Matt, D.W., et al. (1989) Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 68, 1027-1032.
29. Nestler, J.E. & Jakubowicz, D.J. (1996) Decrease on ovarian cytochrome P450c17alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. New England Journal of Medicine, 335, 617-623.
30. Orsini, L.F., Venturoli, S., Lorusso, R., Pluchinotta, V., Paradisi, R. & Bovicelli, L. (1985) Ultrasonic fndings in polycystic ovarian disease. Fertility and Sterility, 43, 709-714.
31. Pasquali, R., Casimirri, F., Venturoli, S., Paradisi, R., Mattioli, L., Capelli, M., Melchionda, N. & Lubò, G. (1983) Insulin resistance in patients with polycystic ovaries: its relationship to body weight androgen levels. Acta Endocrinologica (Copenhagen), 104, 110-115.
32. Pasquali, R., Antenucci, D., Casimirri, F., Venturoli, S., Paradisi, R., Fabbri, R., Balestra, V., Melchionda, N. & Barbara, L. (1989) Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. Journal of Clinical Endocrinology and Metabolism, 68, 173-179.
33. Pasquali, R., Casimirri, F., Platé, L. & Capelli, M. (1990) Characterization of obese women with reduced sex-hormone binding globulin concentrations. Hormone and Metabolic Research, 22, 303-306.
34. Pasquali, R. & Casimirri, F. (1993) The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clinical Endocrinology (Oxford), 39, 1-16.
35. Pasquali, R., Casimirri, F., Venturoli, S., Morselli-Labate, A.M., Reho, S., Pezzoli, A. & Paradisai, R. (1994) Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome. Metabolism, 43, 706-713.
36. Plymate, S.R., Matej, L.A., Jones, R.E. & Friedl, K.E. (1988) Inhibition of sex hormone-binding globulin production in the human hepathoma (HepG2) cell line by insulin and prolactin. Journal of Clinical Endocrinology and Metabolism, 67, 460-464.
37. Poretsky, L. (1991) On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocrine Review, 12, 3-13.
38. Schaison, G. & Couzinet, B. (1997) Use of drugs to suppress ovarian hyperandrogenism. In: Androgen Excess Disorders in Women (eds R. Azziz, J.E. Nestler & D. Dewailly), pp. 715-725. Lippincot-Raven, Philadelphia.
39. Sheu, W.H.H., Hsu, C.H., Chen, Y.S., Jeng, C., Y. & Fuh, M.M.S. (1994) Prospective evaluation of insulin resistance and lipid metabolism in women receiving oral contraceptives. Clinical Endocrinology (Oxford), 40, 249-255.
40. Siegel, S. (1956) Nonparametric Statistics for the Behavioural Sciences. McGraw-Hill. New York, NY.
41. Snedecor, G.W. & Cochran, W.G. (1989) Statistical Methods, 8th edn. Iowa State University Press, Ames.
42. Stevenson, J.C., Crook, D., Godsland, I.F., Collins, P. & Whitehead, M.I. (1994) Hormone replacement therapy and the cardiovascular system. Drugs, 47 (suppl. 2), 35-41.
43. Strauss, J.S. (1987) Sebaccous glands. In: Dermatology in General Medicine, 3rd edn (eds T.B. Fitzpatrik, A.Z. Elsen & K Wolff), pp. 666-685. McGraw-Hill, New York, NY.
44. The Writing Group for the PEPI Trial (1995) Effects of estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Intervention (PEPI) trial. Journal of American Medical Association, 273, 199-208.
45. den Tonkelaar, I., Seidell, J.C., van Noord, P.A.H., Baanders-van Halewijn, E.A. & Ouwehand, I.J. (1990) Fat distribution in relation to age, degree of obesity, smoking habits, parity and estrogen use: a cross sectional study in 11825 Dutch women participating in the DOM-Project. International Journal of Obesity, 14, 753-761.
46. Velasquez, E.M., Mendoza, S., Hamer, T., Sosa, F. & Glucck, C.J. (1994) Metformin therapy in polycystic ovary syndrome reduces hyperinsulinaemia, insulin resistance, hyperandrogenaemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism, 43, 647-654.
47. Watanabe, R.M., Azen, C.G., Roy, S., Perlman, J.A. & Bergmann, R.M. (1994) Defects in carbohydrate metabolism in oral contraceptive users without apparent metabolic risk factors. Journal of Clinical Endocrinology and Metabolism, 79, 1277-1283.
48. Wild, R.A., Painter, P.C., Coulson, P.B., Carruth, K.B. & Ranney, G.B. (1985) Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 61, 946-951.